Capricor Therapeutics, Inc. (NASDAQ:CAPR)
| Market Cap | 649.77M+81.0% |
| Revenue (ttm) | 0-100.0% |
| Net Income | -147.50M-79.9% |
| EPS | -2.64-46.7% |
| Shares Out | 57.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,987,259 |
| Open | 9.85 |
| Previous Close | 8.87 |
| Day's Range | 9.01 - 11.23 |
| 52-Week Range | 2.96 - 40.37 |
| Beta | 0.53 |
| Analysts | Buy |
| Price Target | 12.70(+13.19%) |
| Earnings Date | Mar 11, 2027 |
About CAPR
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
4 firms rating CAPR in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 11, 2027Earnings report
$CAPR stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CAPR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CAPR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CAPR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CAPR Revenue by Segment
| Potential milestone payments | $89.00M | 87.67% |
| Upfront payment | $12.00M | 11.82% |
| Milestone payments accrued | $500.00K | 0.49% |
| Minimum annual royalty payments | | $20.00K | 0.02% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CAPR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CAPR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CAPR
| XBIState Street SPDR S&P Biotech ETF | $16.40M |
| VTIVanguard Morningstar Total Stock Market ETF | $15.68M |
| IWMiShares Russell 2000 ETF | $12.41M |
| VXFVanguard Extended Market ETF | $5.65M |
| IWOiShares Russell 2000 Growth ETF | $4.46M |
| VTWOVanguard Russell 2000 ETF | $2.96M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CAPR’s recent data — informational, not investment advice
What’s Behind the Score
News check: Deramiocel approaching PDUFA decision with positive clinical validation; offset by Q3 net loss expansion and 10% workforce reduction.